A previously published randomized clinical trial showed that vildagliptin administration (at a daily dose of 50 mg) with iftar meal (together with pre-meal insulin iftar bolus) for the entire month of Ramadan (4 weeks) significantly mitigated postprandial hyperglycemia, increased TIR 70–180 mg/dL, and reduced glycemic variability among Egyptian adolescents and young adults with T1D who were using the MiniMedTM 780G AHCL system (Medtronic, Northridge, CA, USA) [134]. This evidence concerns the gene INS and Hyperglycemia.